In a nutshell The study evaluated the impact of granulocyte-colony stimulating factor (G-CSF; Neupogen) on the outcomes of brentuximab-vedotin (BV; Adcetris) plus chemotherapy in newly diagnosed patients with stage-III/IV Hodgkin lymphoma (HL). The authors found that G-CSF improved the safety and efficacy outcomes of the combination therapy in such...
Read More
In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...
Read More
In a nutshell This trial was carried out to examine the effectiveness and safety profile of pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of classical Hodgkin lymphoma (cHL) that has relapsed and is refractory (resistant to drug treatment). The authors found that...
Read More
In a nutshell This overview discusses initial treatment options for classical Hodgkin lymphoma (cHL). Some background Classical HL is a cancer of the lymph nodes. Early-stage (stage I/II) cHL is contained to half the body, while advanced (stage III/IV) has spread to both the upper and lower halves of the body. Both early and advanced cHL have...
Read More
In a nutshell This study looked at the lung function of patients with classical Hodgkin lymphoma (HL) in the first years of remission. It found that these survivors had higher rates of lung damage. Some background HL is a cancer of the lymph nodes which most often affects children and young adults. HL has good outcomes, and most patients with HL will...
Read More
In a nutshell This study aimed to investigate the real-world safety and effectiveness of brentuximab vedotin (BV) and bendamustine before stem cell transplant (SCT) for patients with relapsed or refractory classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective as...
Read More
In a nutshell The study evaluated whether exposure to checkpoint blockade therapy (CBT) can make relapsed/refractory (R/R) Hodgkin lymphoma (HL) sensitive to further treatments. The main finding was that CBT may make patients with R/R-HL responsive to further treatments. Some background While a large percentage of patients with HL can ve cured with...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of allogeneic stem cell transplantation (alloSCT) after immune checkpoint inhibitor (ICI) treatment in patients with classic Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and has very good outcomes in these...
Read More
In a nutshell The study evaluated the outcomes of second autologous stem cell transplantation (ASCT2) in patients with relapsed/refractory Hodgkin lymphoma (r/r-HL) after a first transplantation (ASCT1). The main finding was that ASCT2 was safe and relatively effective in such patients. Some background ASCT replaces cancerous bone marrow with healthy...
Read More
Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...
Read More
In a nutshell This study looked at the effect of pembrolizumab (Keytruda) to treat classical Hodgkin lymphoma (cHL) which had relapsed after previous treatments including brentuximab vedotin (Adcetris). It found that pembrolizumab was effective for these patients. Some background cHL is typically treated with chemotherapy, and sometimes with radiation...
Read More
In a nutshell This study looked at the targeted therapy nivolumab (Opdivo) to treat relapsed classical Hodgkin lymphoma (cHL). It found that most patients with relapsed cHL responded to nivolumab. Some background HL is a cancer of the lymph nodes which has good treatment options. However, roughly a third of patients with cHL will have the cancer...
Read More
